Nebulised interferon beta-1a for patients with COVID-19

por Peiffer-Smadja, Nathan, Yazdanpanah, Yazdan
Publicado 2021

Mpox: a new name for a new disease?

por Beaumont, Anne-Lise, Peiffer-Smadja, Nathan
Publicado 2023

Predatory journals in anaesthesiology and critical care: what to know and how to avoid pitfalls!

por Rozencwajg, Sacha, Peiffer-Smadja, Nathan, James, Arthur, Kantor, Elie
Publicado 2022

COVID-19 : les thérapeutiques

por KHERABI, Yousra, LESCURE, François-Xavier, YAZDANPANAH, Yazdan, PEIFFER-SMADJA, Nathan
Publicado 2022

COVID-19: Brief overview of therapeutic strategies

por Beaumont, Anne-Lise, Rozencwajg, Sacha, Peiffer-Smadja, Nathan, Montravers, Philippe
Publicado 2023

COVID-19 vaccines: A race against time

por Peiffer-Smadja, Nathan, Rozencwajg, Sacha, Kherabi, Yousra, Yazdanpanah, Yazdan, Montravers, Philippe
Publicado 2021

Vaccins COVID-19 : une course contre la montre

por Peiffer-Smadja, Nathan, Rozencwajg, Sacha, Kherabi, Yousra, Yazdanpanah, Yazdan, Montravers, Philippe
Publicado 2021

Type 1 interferons as a potential treatment against COVID-19

por Sallard, Erwan, Lescure, François-Xavier, Yazdanpanah, Yazdan, Mentre, France, Peiffer-Smadja, Nathan
Publicado 2020

COVID-19 vaccine boosters: What do we know so far?

por Kherabi, Yousra, Fiolet, Thibault, Rozencwajg, Sacha, Salaün, Jean-Philippe, Peiffer-Smadja, Nathan
Publicado 2021

Dose de rappel du vaccin COVID-19 : que savons-nous à ce jour ?

por Kherabi, Yousra, Fiolet, Thibault, Rozencwajg, Sacha, Salaün, Jean-Philippe, Peiffer-Smadja, Nathan
Publicado 2022

Hydroxychloroquine and COVID-19: a tale of populism and obscurantism

por Peiffer-Smadja, Nathan, Rebeaud, Mathieu E, Guihur, Anthony, Mahamat-Saleh, Yahya, Fiolet, Thibault
Publicado 2021

Ecological Momentary Assessment Using Smartphones in Patients With Depression: Feasibility Study

por Maatoug, Redwan, Peiffer-Smadja, Nathan, Delval, Guillaume, Brochu, Térence, Pitrat, Benjamin, Millet, Bruno
Publicado 2021

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

por Fiolet, Thibault, Kherabi, Yousra, MacDonald, Conor-James, Ghosn, Jade, Peiffer-Smadja, Nathan
Publicado 2022

Omicron SARS-CoV-2 variant: What we know and what we don’t

por Ferré, Valentine Marie, Peiffer-Smadja, Nathan, Visseaux, Benoit, Descamps, Diane, Ghosn, Jade, Charpentier, Charlotte
Publicado 2022

Préconisations pour protéger les patients de la filière oncologique face au variant Omicron

por Barrière, Jérôme, Zalcman, Gérard, Fignon, Laurent, Peiffer-Smadja, Nathan, Audigier-Valette, Clarisse, Carles, Michel
Publicado 2022

Clinical Decision Support Systems for Antibiotic Prescribing: An Inventory of Current French Language Tools

por Durand, Claire, Alfandari, Serge, Béraud, Guillaume, Tsopra, Rosy, Lescure, François-Xavier, Peiffer-Smadja, Nathan
Publicado 2022

Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19

por Ader, Florence, Bouscambert-Duchamp, Maude, Hites, Maya, Peiffer-Smadja, Nathan, Mentré, France, Burdet, Charles
Publicado 2022

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis

por Fiolet, Thibault, Guihur, Anthony, Rebeaud, Mathieu Edouard, Mulot, Matthieu, Peiffer-Smadja, Nathan, Mahamat-Saleh, Yahya
Publicado 2021

Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response

por Fiolet, Thibault, Guihur, Anthony, Rebeaud, Mathieu Edouard, Mulot, Matthieu, Peiffer-Smadja, Nathan, Mahamat-Saleh, Yahya
Publicado 2021

Re: effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: author's response

por Fiolet, Thibault, Guihur, Anthony, Rebeaud, Mathieu Edouard, Mulot, Matthieu, Peiffer-Smadja, Nathan, Mahamat-Saleh, Yahya
Publicado 2021